AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 261 min read$TXG

Taich Adam sold $1.1M of TXG

Taich Adam (Chief Financial Officer) sold 17,166 shares of 10x Genomics, Inc. (TXG) at $63.02 ($1.08M total) on 2026-08-24.

Original reporting
SEC EDGAR · Taich Adam
Published Aug 26, 2026, 8:44 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TXG
Bearish
medium confidence
Mentioned
$TXG
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TXGBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, useful for short-term trading decisions.

02

Market read

Insider sale adds a modest bearish nuance to 10x Genomics' stock outlook.

03

What to watch

The CFO's holdings remain sizable; no immediate dilution risk.

Relevance 6/10Novelty 5/10Timing: filed on 2026-08-26

Background

Form 4 filings disclose insider transactions; investors monitor them for potential signals.

Company-level read

Ticker impact

$TXGBearishMedium confidence
Context

CFO Taich Adam sold 17,166 shares of 10x Genomics for $1.08M, reducing his stake to 362,732 shares.

Expected impact

Possible modest downside pressure in the next trading session.

Evidence & confidence

A $1M sale by a senior officer is material for a mid-cap biotech, but the amount is modest relative to market cap.

Market effects

Sector

May prompt scrutiny of insider activity in biotech sector.

Regional

Limited to US biotech investors.

Global

Low

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    10x Genomics, Inc.

    Biotech firm developing genomic analysis platforms.

  • Person
    Taich Adam

    Chief Financial Officer of 10x Genomics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TXG insider trading history →

Related articles

SEP 3
$TXGMed

10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?

10x Genomics (TXG) has risen 84% in 3 months, driven by consumables growth and Atera demand. Q2 2026 consumables revenue increased 7% YoY, with Single Cell up 3% and Spatial up 16%. Management raised 2026 revenue guidance to $610M-$630M. However, instrument sales fell 47.2% YoY, and the company reported a $19.6M operating loss. TXG trades at 11.9X forward sales, a premium to peers.

tradingview.com3 min
AUG 18
$TXGMed

10x Genomics (TXG) Sees Strong Early Orders for New Atera Platform

10x Genomics (NASDAQ:TXG) reported Q2 revenue of $151m, including a $1.6m Takara settlement; excluding it, revenue was $149.4m, up 3% YoY. Atera booked orders already exceed planned 2026 shipments (~40 units). Cash rose to $552m and gross margin to 74%. Full-year revenue guidance raised to $610m-$630m; instrument revenue fell 47% YoY.

yahoo.com3 min
AUG 14
$TXGMedAI 9/10

10x Genomics (TXG) Q2 2026 Earnings Call Transcript

10x Genomics (TXG) reported Q2 2026 revenue of $151.0 million, up 3% YoY excluding non-recurring patent settlement revenue. Gross margin was 74%. FY2026 revenue guidance is $610 million to $630 million. Booked Atera orders exceed the 2026 shipment target of 40 units, with capacity as the constraint. Net loss was $17.9 million.

fool.com10 min
AUG 11
$TENXMed

A Wild Day In Biotech

Biotech stocks moved sharply after clinical and guidance updates. Tenax Therapeutics (TENX) fell nearly 90% after its Phase 3 LEVEL trial of TNX-103 missed primary and key secondary endpoints. AbCellera Biologics (ABCL) rose on Phase 2 results for ABCL635 in menopausal vasomotor symptoms. 10x Genomics (TXG) gained after raising full-year revenue guidance and citing strong early Atera demand.

zerohedge.com6 min